Stereotactic biopsy versus spectroscopy in cases of gliomas with a high degree of malignancy. A review of the literature;Biopsia estereotáctica frente a espectroscopia en gliomas de alto grado de malignidad. Revisión de la bibliografía

Revista de Neurologia

Volumn 47, Issue 6, 2008, Pages 310-314

  González Bonet, Luis Germán ^a  

^a HOSPITAL GENERAL UNIVERSITARIO DE VALENCIA   (Spain)

Author keywords

Biopsy; Diagnostic errors; Magnetic resonance spectroscopy; Malignant primary brain tumors; Stereotaxic technics; Surgical diagnostic technics

Indexed keywords

DIAGNOSTIC ACCURACY; DISEASE SEVERITY; GLIOMA; HUMAN; MORBIDITY; MORTALITY; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PREDICTION AND FORECASTING; REVIEW; SENSITIVITY AND SPECIFICITY; STEREOTACTIC BIOPSY; SURVIVAL TIME; SYSTEMATIC REVIEW; BIOPSY; METHODOLOGY; NERVOUS SYSTEM TUMOR; PATHOLOGY; SPECTROSCOPY; STEREOTACTIC PROCEDURE;

BIOPSY; GLIOMA; HUMANS; NERVOUS SYSTEM NEOPLASMS; PREDICTIVE VALUE OF TESTS; SENSITIVITY AND SPECIFICITY; SPECTRUM ANALYSIS; STEREOTAXIC TECHNIQUES;

EID: 52649133453     PISSN: 02100010     EISSN: None     Source Type: Journal    
DOI: 10.33588/rn.4706.2008370     Document Type: Review

References (45)

1. Apuzzo MLJ. Commentary: epidemiology and data analysis. In Apuzzo MLJ, ed. Malignant cerebral glioma. Park Ridge: AANS; 1990. p. 111.
2. Salcman M. Epidemiology and factors affecting survival. In Apuzzo MLJ, ed. Malignant cerebral glioma. Park Ridge: AANS; 1990. p. 95-109.
3. Curran WJ, Scott CB, Horton J, Nelson JS, Weinstein AS, Fischbach AJ, et al. Recursive partitioning analysis of prognostic factors in three Radiation Therapy Oncology Group malignant glioma trials. J Natl Cancer Inst 1993; 85: 704-10.
4. Burger PC, Scheithauer BW. Atlas of tumor pathology: tumors of the central nervous system. Washington, DC: Armed Forces Institute of Pathology; 1994.
5. Burger PC, Vogel FS, Green SB, Strike TA. Glioblastoma multiforme and anaplastic astrocytoma: pathologic criteria and prognostic implications. Cancer 1985; 56: 1106-11.
6. Cohadon F, Aouad N, Rougier A, Vital C, Rivel J, Dartigues JF. Histologic and non-histologic factors correlated with survival time in supratentorial astrocytic tumors. J Neurooncol 1985; 3: 105-11.
7. Kim TS, Halliday AL, Hedley-Whyte ET, Convery K. Correlates of survival and the Daumas-Duport grading system for astrocytomas. J Neurosurg 1991; 74: 27-37.
8. Apuzzo MLJ, Chandrasoma PT, Cohen D, Zee CS, Zelman V. Computed imaging stereotaxy: experience and perspective related to 500 procedures applied to brain masses. Neurosurgery 1987; 20: 930-7.
9. Ostertag CB, Mennel HD, Kiessling M. Stereotactic biopsy of brain tumors. Surg Neurol 1980; 14: 275-83.
10. Coffey RJ, Lunsford LD, Taylor FH. Survival after stereotactic biopsy of malignant gliomas. Neurosurgery 1998; 22: 465-73.
11. Kelly PJ, Daumas-Duport C, Kispert DB, Kall BA, Scheithauer BW, Illig JJ. Imaging-based stereotaxic serial biopsies in untreated intracranial glial neoplasms. J Neurosurg 1987; 66: 865-74.
12. Chandrasoma PT. Problems relating to pathological interpretation in stereotactic biopsy procedures. In Apuzzo MLJ, ed. Brain surgery: complication avoidance and management. New York: Churchill-Livingstone; 1993. p. 425-31.
13. Kimura T, Sako K, Gotoh T, Tanaka K, Tanaka T. In vivo single-voxel proton MR spectroscopy in brain lesions with ring-like enhancement. NMR Biomed 2001; 14: 339-49.
14. Wilken B, Dechent P, Herms J, Maxton C, Markakis E, Hanefeld F, et al. Quantitative proton magnetic resonance spectroscopy of focal brain lesions. Ped Neurol 2000; 23: 22-31.
15. Fayed-Miguel N, Morales-Ramos H, Modrego-Pardo PJ. Resonancia magnética con espectroscopia, perfusión y difusión cerebral en el diagnóstico de los tumores cerebrales. Rev Neurol 2006; 42: 735-42.
16. Arnold DL, Shoubridge EA, Villemure JG, Feindel W. Proton and phosphorus magnetic resonance spectroscopy of human astrocytomas in vivo: preliminary observations on tumor grading. NMR Biomed 1990; 3: 184-9.
17. McBride DQ, Miller BL, Nikas DL, Buchthal S, Chang L, Chiang F, et al. Analysis of brain tumors using 1H magnetic resonance spectroscopy. Surg Neurol 1995; 44: 137-44.
18. Kim JH, Gildenberg PL. Stereotactic biopsy. In Gildenberg PL, Tasker RR, eds. Textbook of stereotactic and functional neurosurgery. New York: McGraw-Hill; 1998. p. 387-96.
19. Bernstein M, Parrent AG. Complications of CT-guided stereotactic biopsy of intra-axial brain lesions. J Neurosurg 1994; 81: 165-8.
20. Hall WA. The safety and efficacy of stereotactic biopsy for intracranial lesions. Cancer 1998; 82: 1749-55.
21. Mundinger F. CT stereotactic biopsy for optimizing the therapy of intracranial processes. Acta Neurochir Suppl (Wien) 1985; 35: 70-4.
22. Sawin PD, Hitchon PW, Follett KA Torner JC. Computed imaged-assisted stereotactic brain biopsy: a risk analysis of 225 consecutive cases. Surg Neurol 1998; 49: 640-9.
23. Kim JE, Kim DG, Paek SH, Juming HW. Stereotactic biopsy for intracranial lesions: reliability and its impact on the planning of treatment. Acta Neurochir 2003; 145: 547-55.
24. Voges J, Schroder R, Treuer H, Pastyr O, Schlegel W, Lorenz WJ, et al. CT-guided and computer assisted stereotactic biopsy. Technique, results, indications. Acta Neurochir 1993; 125: 142-9.
25. Liu Z, Yu X, Li S, Chen L, Du J, Liu R, et al. Stereotactic biopsy for intracranial deep lesions. Zhonghua Yi Xue Za Zhi 2002; 82: 225-8.
26. Broggi G, Franzini A, Giorgi C, Allegranza A. Diagnostic accuracy and multinodal approach in stereotactic biopsies of deep brain tumors. Acta Neurochir Suppl 1984; 33: 211-2.
27. Kleihues P, Volk B, Anagnostopoulos J, Kiessling M. Morphologic evaluation of stereotactic brain tumour biopsies. Acta Neurochir Suppl 1984; 33: 171-81.
28. Scerrati M, Rossi GF. The reliability of stereotactic biopsy. Acta Neurochir Suppl 1984; 33: 201-5.
29. Chandrasoma PT, Smith MM, Apuzzo ML. Stereotactic biopsy in the diagnosis of brain masses: comparison of results of biopsy and resected surgical specimen. Neurosurgery 1989; 24: 160-5.
30. Feiden W, Steude U, Bise K, Gundisch O. Accuracy of stereotactic brain tumour biopsy: comparison of the histologic findings in biopsy cilindres and resected tumor tissue. Neurosurg Rev 1991; 14: 51-6.
31. Jackson RJ, Fuller GN, Abi-Said D, Lang FF, Gokaslan ZL, Shi WM, et al. Limitations of stereotactic biopsy in the initial management of gliomas. Neurooncology 2001; 3: 193-200.
32. Aker FV, Hakan T, Karadereler S, Erkan M. Accuracy and diagnostic yield of stereotactic biopsy in the diagnosis of brain masses: comparison of results of biopsy and resected surgical specimens. Neuropathology 2005; 25: 207-13.
33. Gaudin PB, Sheman ME, Brat DJ, Zahurak M, Erozan YS. Accuracy of grading gliomas on CT-guided stereotactic biopsies: a survival analysis. Diagn Cytopathol 1997; 17: 461-6.
34. Revesz T, Scaravilli F, Coutinho L, Cockburn H, Sacares P, Thomas DG. Reliability of histological diagnosis including grading in gliomas biopsied by image-guided stereotactic technique. Brain 1993; 116: 781-93.
35. Willems JG, Alva-Willems JM. Accuracy of cytologic diagnosis of central nervous system neoplasm in stereotactic biopsies. Acta Cytol 1984; 24: 243-9.
36. Adamson AJ, Rand SD, Prost RW, Kim TA, Schultz C, Haughton VM. Focal brain lesions: effect of single-voxel proton MR spectroscopic findings on treatment decisions. Radiology 1998; 209: 73-8.
37. Rand SD, Prost R, Haughton V, Mark L, Strainer J, Johansen J, et al. Accuracy of single-voxel proton MR spectroscopy in distinguishing neoplastic from non-neoplastic brain lesions. AJNR Am J Neuroradiol 1997; 18: 1695-704.
38. Lin A, Blunl S, Mamelak AN. Efficacy on proton magnetic resonance spectroscopy in clinical decision making for patients with suspected malignant brain tumors. J Neurooncol 1999; 45: 69-81.
39. Preul MC, Caramanos Z, Collins DL, Villemure JG, Leblanc R, Olivier A, et al. Accurate, noninvasive diagnosis of human brain tumors by using proton magnetic resonance spectroscopy. Nat Med 1996; 2: 323-25.
40. Law M, Yang S, Wang H. Babb JS, Johnson G, Cha S, et al. Glioma grading: sensitivity, specificity, and predictive values of perfusion MR imaging and proton MR spectroscopic imaging compared with conventional MR imaging. AJNR Am J Neuroradiol 2003; 24: 1989-98.
41. Majós C, Julià-Sapé M, Alonso J, Serrallonga M, Aguilera C, Acebes JJ, et al. Brain tumor classification by proton MR spectroscopy: comparison of diagnostic accuracy at short and long TE. AJNR Am J Neuroradiol 2004; 25: 1696-704.
42. Kuznetsov YE, Caramanos Z, Antel SB, Preul MC, Leblanc R, Villemure JG, et al. Proton magnetic resonance spectroscopic imaging can predict length of survival in patients with supratentorial gliomas. Neurosurgery 2003; 53: 565-74.
43. Hegi ME, Diserens AC, Gorlia T, Hamou MF, De Tribolet N, Weller M, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 2005; 352: 997-1003.
44. Cairncross JG, Ueki K, Zlatescu M, Lisle DK, Finkelstein DM, Hammond RR, et al. Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas. J Natl Cancer Inst 1998; 90: 1473-9.
45. Smith JS, Perry A, Borell TJ, Lee HK, O'Fallon J, Hosek SM, et al. Alterations of chromosome arms 1p and 19q as predictors of survival in oligodendrogliomas, astrocytomas, and mixed oligoastrocytomas. J Clin Oncol 2000; 18: 636-45.